OncoCyte company info

What does OncoCyte do?
OncoCyte (NASDAQ:OCX) specializes in the development and commercialization of novel, non-invasive diagnostics for early detection and monitoring of cancer. With a focus on lung cancer, the company aims to provide reliable diagnostic solutions that can improve patient outcomes and assist healthcare providers in making more informed treatment decisions. OncoCyte's projects include the development of liquid biopsy tests designed to detect cancer at its earliest stages. The company's objective is to become a key player in the field of cancer diagnostics by expanding its product pipeline and leveraging cutting-edge technology to address unmet needs in oncology care.
OncoCyte  company media
Company Snapshot

Is OncoCyte a public or private company?

key
Ownership
Public

How many people does OncoCyte employ?

people
Employees
45

What sector is OncoCyte in?

pie chart
Sector
Health Care

Where is the head office for OncoCyte ?

location pin
Head Office
Irvine, United States

What year was OncoCyte founded?

founded flag
Year Founded
2009
What does OncoCyte specialise in?
/Cancer Diagnosis /Liquid Biopsy /Pharmaceutical Research /DetermaDx Test /Diagnostic Services /Clinical Trials

What are the products and/or services of OncoCyte ?

Overview of OncoCyte offerings
DetermaRx, a treatment stratification test that identifies non-small cell lung cancer patients who may benefit from adjuvant chemotherapy following surgical resection.
DetermaIO, a diagnostic test used to identify patients likely to respond to immune-oncology therapies.
DetermaCNI, a blood-based test designed to monitor cancer treatment effectiveness and disease recurrence.
Pharma Services, offering pharmaceutical companies access to expertise in biomarker and assay development for precision medicine.

Who is in the executive team of OncoCyte ?

OncoCyte leadership team
  • Mr. Joshua  Riggs
    Mr. Joshua Riggs
    President, CEO & Director
  • Mr. James  Liu
    Mr. James Liu
    Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
  • Dr. Ekkehard  Schutz M.D., Ph.D.
    Dr. Ekkehard Schutz M.D., Ph.D.
    Chief Science Officer
  • Mr. Peter  Hong
    Mr. Peter Hong
    VP, General Counsel & Secretary
  • Mr. Yuh-Min  Chiang Ph.D.
    Mr. Yuh-Min Chiang Ph.D.
    Senior Vice President of R&D and Product Development
  • Ms. Sandra  O'Donald
    Ms. Sandra O'Donald
    Senior Vice President of Business Operations
  • Dr. Michael D. West Ph.D.
    Dr. Michael D. West Ph.D.
    Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
  • Ms. Sara  Riordan
    Ms. Sara Riordan
    Director of Medical Education